Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01951274 | VPD-737 for Treatment of Chronic Pruritus | PHASE2 | COMPLETED | 257 | — | — | Oct 15, 2013 | Dec 2, 2014 | May 13, 2022 | 25 | United States |
| Arm | Type | Description |
|---|---|---|
| 0.25 mg VPD-737 | EXPERIMENTAL | 0.25 mg of VPD-737 daily by mouth for 42 days |
| 1 mg VPD-737 | EXPERIMENTAL | 1 mg VPD-737 taken daily by mouth for 42 days |
| 5 mg VPD-737 | EXPERIMENTAL | 5 mg tablets of VPD-737 to be taken daily by mouth for 42 days |
| Placebo | PLACEBO_COMPARATOR | placebo tablets to be taken daily by mouth for 42 days |
| Name | Type | Description |
|---|---|---|
| VPD-737 | DRUG | NK1 Receptor Antagonist |
| Placebo | DRUG | - |
Inclusion Criteria: * Clinical diagnosis of chronic pruritus and unresponsive to current therapies Exclusion Criteria: * Have chronic liver or renal disease